Injectables Solutions

AdhereIT® is a connected medical device that enhances patient adherence for self-injecting medication. It supports training and autoinjector devices, alleviating anxieties and promoting proper usage. Through multisensory feedback and app features, AdhereIT® enables patients to start treatment sooner an...

Noble's patient-centric training devices, mimic real drug delivery devices to improve self-administered therapies. They enhance patient experience, promote adherence, and boost health outcomes. These fully resettable and reusable devices offer a realistic drug delivery simulation, allowing patients to ...

PADA (Powder Administration Device for Animals) is a specialized kit by Aptar Pharma for pre-clinical pulmonary research. It allows precise and efficient powder delivery to mouse lungs, aiding early-stage drug development for asthma, COPD, lung cancers, and cystic fibrosis.

Aptar Digital Health is a leading provider of integrated health solutions and services. We offer a comprehensive range of patient-centric digital solutions that utilize our expertise and diverse product portfolio to deliver exceptional experiences and better outcomes.

At Aptar Pharma, we meet evolving dermal drug delivery needs, prioritizing patient safety and risk reduction. With the widest range of Airless devices, we support the increasing demand for dermal drug delivery solutions.

Aptar Pharma's extensive portfolio of eye care solutions, boasting more than 400 market references, has solidified its position as the leading platform for ophthalmic drug delivery. With a constant focus on innovation and continuous growth, Aptar Pharma has become the preferred choice for meeting the n...

Aptar Pharma is a renowned producer of proprietary nasal device systems, specializing in Unidose, Bidose, and multi-dose options, known for their exceptional quality and reliability.

Aptar Pharma offers diverse delivery options and aims to accelerate your drug development process while minimizing risks. Their solutions encompass oral, ear and throat, buccal, vaginal, and anal treatments.

Aptar Pharma is a global leader in pulmonary drug delivery devices for asthma and COPD. We offer a wide range of pMDI technology platforms, including metering valves, dose counters, BAIs, and DPIs, designed to optimize treatment and management for patients.

Aptar Pharma's specialized analytical, development and regulatory services contribute value throughout the entire drug development process, expediting progress and mitigating risks along the journey.

Aptar CSP Technologies is a leading expert in active material science solutions, specializing in delivering cutting-edge active packaging solutions designed to safeguard delicate products.

Aptar Pharma’s PremiumCoat® platform comprises an end-to-end package of products, data and services for containing and protecting sensitive drug formulations in vials or pre-filled syringes (PFS). PremiumCoat® ETFE film-coated Bromobutyl closure solutions include stoppers for 13mm/20mm vials, plungers for ...

Aptar Pharma's presentation entitled "Innovations in Inhalation" explores the current extensive portfolio of high-quality OINDP (Orally Inhaled and Nasal Drug Products) delivery devices. The presentation also highlights Aptar Pharma's comprehensive services which support respiratory drug development, including device selection, formulation development, analytical methods, and regulatory support. A key focus of the talk is the introduction of Orbital, an innovative high payload DPI system designed to enhance drug delivery efficiency and patient compliance. This discussion aims to showcase Aptar Pharma's latest advancements in inhalation technology, emphasizing their commitment to improving patient care through innovative drug delivery systems.

Big Pharma reports that up to over 90% of their CO2 emissions are scope 3. This is not only a huge burden but also the most difficult part to influence for pharmaceutical industry. However, there are ways to manage and collaborate in the industry. Christophe Marie from Aptar Group will highlight how Aptar implemented specific targets with partners and suppliers to tackle the scope 3 challenge, coming from a consumer market perspective, extrapolating into the pharmaceutical business. Also, when talking about products we are increasingly facing requests to minimize our CO2 footprint in Pharma. A great example for collaborative approaches helping to de-risk and accelerate our clients’ low GWP pressurized Metered Dose Inhaler (pMDI) programs will be illustrated by Chris Baron, based on the transition of the current pMDIs to alternative low GWP propellant technologies. Join Christophe Marie and Chris Baron at CPHI to learn how Aptar Pharma supports more sustainable product

Aptar Pharma Brochure